
|Articles|May 3, 2021
The Mainstream Patient: May 3, 2021
Author(s)Morgan Petronelli
This week’s edition of The Mainstream Patient features stories on skin care pilling, mandelic acid, fungal acne, hyperpigmentation, and more.
Advertisement
In this week’s edition, Allure explains how to prevent your skin care products from pilling and if you’re over-exfoliating. Also, Hello Giggles dives into the benefits of mandelic acid in skin care and how to tell if your acne is actually fungal acne. Finally, Shape details what specific serums do to the skin and Women’s Health features 1 dermatologist’s skin care routine to treat hyperpigmentation.
Advertisement
Related to this article

For Healthy Skin Month, a dermatology nurse practitioner shares why sunscreen matters in winter and how clinicians can close gaps in skin cancer screening.

Learn why indoor tanning remains a preventable source of melanoma, what research suggests about why some patients experience difficulty stopping, and how a clinical pilot called TanPrevent could connect education with follow-up support to help them quit and stay quit.

Bioelements and Celluma partnered to educate estheticians on integrating LED light therapy into customized facial treatments for acne and aging skin.

FDA implements updated iPLEDGE REMS requirements for isotretinoin, allowing at-home pregnancy testing and reducing prescription and counseling burdens.

Bosakitug failed to meet primary and secondary endpoints in a phase 2 atopic dermatitis trial despite evidence of TSLP target engagement.

Recent dermatology research explores chronic hand eczema prevalence, cancer risk in morphea, pernio, biologic optimization in HS, and melanoma risk prediction.

Hypochlorous acid sprays are trending as a post-gym skin care essential, but can they actually prevent sweat-related breakouts?
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Implements Updated iPLEDGE REMS Requirements for Isotretinoin
2
Monitoring and Treatment Selection for Oral TYK2 Inhibitors in Psoriasis
3
Bioelements and Celluma Collaborate on LED Facial Treatments
4
Aclaris' Bosakitug Misses Phase 2 Endpoints in Atopic Dermatitis
5

